Discriminant cognitive factors in responder and non-responder patients with schizophrenia

No abstract is available for this paper.

• Publication year

  1999

• Venue

  European psychiatry

• Publication date

  1999-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/S0924-9338(99)00223-0PMID 10683630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Should schizophrenia be treated as a neurocognitive disorder?

  1999cited by this paper
• Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.

  1999cited by this paper
• Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.

  1999cited by this paper
• Symptoms and cognition as predictors of community functioning: a prospective analysis.

  1999cited by this paper
• The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

  1999cited by this paper
• Cognitive substrates of thought disorder, I: the semantic system.

  1998cited by this paper
• Comparaison du Leponex® avec la rispéridone dans les schizophrénies chroniques sévères

  1998cited by this paper
• Verbal fluency in schizophrenia: The role of semantic clustering in category instance generation

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

  1997cited by this paper
• What are the functional consequences of neurocognitive deficits in schizophrenia?

  1996cited by this paper
• Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy

  1996cited by this paper
• Memory Impairment in Schizophrenia: Perspectives from Psychopathology and Pharmacotherapy

  1996cited by this paper
• Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia

  1996cited by this paper
• [Neurocognitive subtypes of schizophrenia according to performance at verbal fluency tasks].

  1996cited by this paper
• Verbal fluency in dementia of frontal lobe type and dementia of Alzheimer type.

  1995cited by this paper
• New generation of antipsychotic drugs: Novel mechanisms of action: Brunello, N., Mendlewicz, J. and Racagni, G., 150 pp. (International Academy for Biomedical and Drug Research, Vol. 4). Basel: Karger (1993)

  1994cited by this paper
• Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale.

  1994cited by this paper
• Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

  1993cited by this paper
• The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia

  1993cited by this paper
• The neural correlates of the verbal component of working memory

  1993cited by this paper
• The cognitive neuropsychology of schizophrenia

  1993cited by this paper
• Frontal lobe impairment in schizophrenia: relationship to intellectual functioning

  1993cited by this paper
• Negative Features, Retrieval Processes and Verbal Fluency in Schizophrenia

  1993cited by this paper
• Batterie informatise d' valuation de la mmoire inspire de l'approche cognitive

  1993cited by this paper
• Neuropsychological function in schizophrenia. Selective impairment in memory and learning.

  1991cited by this paper
• Differential impairment of semantic and episodic memory in Alzheimer's and Huntington's diseases: a controlled prospective study.

  1990cited by this paper
• The effects of lateralized temporal lobe dysfunction on formal and semantic word fluency.

  1990cited by this paper
• Verbal fluency in Parkinson's disease.

  1990cited by this paper
• Retrieval from semantic and letter-initial categories in patients with Parkinson's disease.

  1989cited by this paper
• Cognitive impairment following frontal lobe damage and its relevance to human amnesia.

  1989cited by this paper
• Schizophrenia: The Major Issues

  1988cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders.

  1988cited by this paper
• Schizophrenic syndromes, cognitive performance and neurological dysfunction

  1987cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• An assessment of verbal recall, recognition and fluency abilities in patients with Huntington's disease.

  1986cited by this paper
• Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease

  1986cited by this paper
• Neuropsychological performance and positive and negative symptoms in schizophrenia.

  1985cited by this paper
• Selective retrieval and free emission of category exemplars in schizophrenia.

  1983cited by this paper
• Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients.

  1983cited by this paper
• Word production and comprehension in Alzheimer's disease: the breakdown of semantic knowledge.

  1983cited by this paper
• [The molecular pathology of schizophrenia].

  1981cited by this paper
• Molecular pathology of schizophrenia: more than one disease process?

  1980cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.

  2016cites this paper
• Speech and language therapies to improve pragmatics and discourse skills in patients with schizophrenia.

  2016cites this paper
• Studies on the Association between Genetic Polymorphisms and Clozapine Drug Response in Treatment Resistant Schizophrenia.

  2013cites this paper
• Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant Schizophrenia.

  2011cites this paper
• The Impact of a Pre-Vocational Program on Cognition, Symptoms, and Work Re-Integration in Schizophrenia

  2009cites this paper
• Cognitive Factors for Predicting Treatment Response in Schizophrenic Patients: One-Year Follow-Up Study

  2008cites this paper
• Multimetric statistical analysis of behavior in mice selected for high and low levels of isolation-induced male aggression.

  2007cites this paper
• Nonverbal behavior of human addicts: multimetric analysis.

  2007cites this paper
• Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.

  2007cites this paper
• Dislipidemias e antipsicóticos atípicos

  2006cites this paper
• Neuropsychologic functioning and structural MRI of the brain in patients with schizophrenia

  2005cites this paper
• Predictors and markers of clozapine response

  2005influential citation
• Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic.

  2004cites this paper
• Treatment goals: response and nonresponse

  2004cites this paper
• The neuropsychology of chronic severe schizophrenic patients treated with clozapine versus treatment as usual

  2003cites this paper
• [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].

  2003cites this paper
• Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.

  2002cites this paper
• Antipsychotic drug treatment: recent advances

  2001cites this paper
• Kognitive Funktionsstörungen bei schizophrenen Psychosen

  2001cites this paper
• Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.

  2001cites this paper
• [Cognitive dysfunction in schizophrenic psychoses. Drug and psychological treatment choices].

  2001cites this paper
• Factores cognitivos que discriminan entre pacientes esquizofrénicos con y sin respuesta al tratamiento

  2000cites this paper